SUBSCRIBE: Print / eNewsletter
INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Ponatinib Shows Promise in CML Even After Early Trial Termination
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
Daratumumab Safe With Myeloma Backbone Therapies
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
Can PET Scan-Guided Therapy Work for Lymphoma?
Two studies presented at the 2014 ASH Meeting addressed whether an interim PET scan during and after an initial therapy can help guide treatment.
Hematopoietic Cell Transplant Safe in HIV-Related Lymphoma
Autologous hematopoietic cell transplantation is a safe and effective treatment option for patients with HIV-associated lymphoma, according to a study presented at ASH 2014.
Pediatric ALL Regimen Improved Survival in Adolescents, Young Adults
A large trial has shown that adolescents and young adults have better event-free and overall survival when treated on an intensive pediatric ALL regimen.
Novel Targeted Agent Shows Promise in Acute Myeloid Leukemia
An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.
T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL
In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.
Sorafenib Demonstrates Activity in AML
In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute myeloid leukemia.
Acute Lymphoblastic Leukemia Responds to Immunotherapy
A single cycle of blinatumomab resulted in complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.